Gilead Sciences, Inc.
NEWS
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) announced a string of approvals, as well as a couple rejections.
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
Kite, a Gilead Company, has inked a worldwide collaboration deal with Sangamo Therapeutics to develop oncology therapeutics.
Achillion is handing out pink slips to 20 percent of its employees and initiating an operational restructuring plan.
Federal court judge orders Merck to repay $2.5 Billion to Gilead in overturned patent decision.
Investors and analysts had been encouraging Gilead to acquire something for a long time, so they were mostly happy when it bought Kite Pharma in September.
The company’s management has a lot on its plate in 2018.
The FDA approved Gilead’s triple combination treatment for HIV, Biktarvy.
Sometimes the biggest are also the best. That’s the case for biotherapeutics stocks.
JOBS
IN THE PRESS